Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.
about
Polycystic liver diseases: advanced insights into the molecular mechanismsUrsodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.Therapeutic Targets in Polycystic Liver Disease.TGR5 in the Cholangiociliopathies.Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.The combination of an HDAC6 inhibitor and a somatostatin receptor agonist synergistically reduces hepato-renal cystogenesis in an animal model of polycystic liver disease.
P2860
Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Centrosomal abnormalities char ...... ed with Cdc25A overexpression.
@en
Centrosomal abnormalities char ...... ed with Cdc25A overexpression.
@nl
type
label
Centrosomal abnormalities char ...... ed with Cdc25A overexpression.
@en
Centrosomal abnormalities char ...... ed with Cdc25A overexpression.
@nl
prefLabel
Centrosomal abnormalities char ...... ed with Cdc25A overexpression.
@en
Centrosomal abnormalities char ...... ed with Cdc25A overexpression.
@nl
P2093
P2860
P1476
Centrosomal abnormalities char ...... ted with Cdc25A overexpression
@en
P2093
Anatoliy I Masyuk
Angela J Stroope
Bing Huang
Brynn N Radtke
Gabriella B Gajdos
Nicholas F LaRusso
Patrick L Splinter
Sergio A Gradilone
Seung-Ok Lee
Tatyana V Masyuk
P2860
P304
P356
10.1016/J.AJPATH.2013.09.021
P407
P577
2013-11-07T00:00:00Z